Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology.
| العنوان: | Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology. |
|---|---|
| المؤلفون: | Kac PR; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden., González-Ortiz F; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden., Emeršič A; Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia., Dulewicz M; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden., Koutarapu S; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden., Turton M; Bioventix Plc, Farnham, GU9 7SX, United Kingdom., An Y; Brain Aging and Behavior Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, United States of America., Smirnov D; Department of Neurosciences, University of California, San Diego, CA 92161 United States of America., Kulczyńska-Przybik A; Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok 15-269, Poland., Varma V; Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, United States of America., Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.; Department of Old Age Psychiatry, King's College London, London SE5 8AF, United Kingdom.; Centre for Age-Related Medicine, Stavanger University Hospital, 4011 Stavanger, Norway.; South London & Maudsley NHS Foundation, NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia, SE5 8AF London, United Kingdom., Montoliu-Gaya L; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden., Camporesi E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden., Winkel I; Dementia Disorders Center, Medical University of Wrocław, 59-330 Scinawa, Poland., Paradowski B; Department of Neurology, Medical University of Wrocław, 50-556 Wroclaw, Poland., Moghekar A; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America., Troncoso JC; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America.; Department of Pathology, John Hopkins University School of Medicine, Baltimore, MD 21287, United States of America., Brinkmalm G; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden., Resnick SM; Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, United States of America., Mroczko B; Department of Neurodegeneration Diagnostics, Medical University of Białystok, Białystok 15-269, Poland., Kvartsberg H; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden., Kramberger MG; Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, 141 52 Huddinge, Sweden., Hanrieder J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1E 6BT, United Kingdom., Čučnik S; Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.; Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.; Department of Rheumatology, University Medical Center Ljubljana, Ljubljana, Slovenia., Harrison P; Bioventix Plc, Farnham, GU9 7SX, United Kingdom., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden.; Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1E 6BT, United Kingdom.; UK Dementia Research Institute, University College London, London, WC1E 6BT, United Kingdom.; Hong Kong Center for Neurodegenerative Diseases, HKCeND, Hong Kong, 1512-1518, China.; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53726, USA., Lewczuk P; Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, 91054, Germany.; Department of Biochemical Diagnostics, University Hospital of Białystok, Białystok, 15-269, Poland., Thambisetty M; Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, United States of America., Rot U; Department of Neurology, University Medical Centre Ljubljana, Ljubljana, 1000, Slovenia.; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia., Galasko D; Department of Neurosciences, University of California, San Diego, CA 92161 United States of America., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, 431 80, Sweden., Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, 431 80, Sweden.; Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, United States of America. |
| المصدر: | MedRxiv : the preprint server for health sciences [medRxiv] 2023 Dec 11. Date of Electronic Publication: 2023 Dec 11. |
| نوع المنشور: | Preprint |
| اللغة: | English |
| بيانات الدورية: | Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE |
| مستخلص: | Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Thereafter, we examined the diagnostic utility of plasma p-tau212. In five cohorts (n=388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations. The diagnostic accuracy and fold changes of plasma p-tau212 were similar to those for p-tau217 but higher than p-tau181 and p-tau231. Immunofluorescent staining of brain tissue slices showed prominent p-tau212 reactivity in neurofibrillary tangles that co-localized with p-tau217 and p-tau202/205. These findings support plasma p-tau212 as a novel peripherally accessible biomarker of AD pathophysiology. Competing Interests: Competing interests MT and PH are employees of Bioventix Plc. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche. KB has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. NJA has given lectures in symposia sponsored by Lilly, BioArctic and Quanterix. The other authors declare no competing interest. |
| التعليقات: | Update in: Nat Commun. 2024 Mar 23;15(1):2615. (PMID: 38521766) |
| References: | Mol Neurodegener. 2023 Mar 16;18(1):18. (PMID: 36927491) Alzheimers Dement. 2022 Jun;18(6):1203-1234. (PMID: 34757693) Alzheimers Dement. 2023 Apr;19(4):1393-1402. (PMID: 36150024) BMC Bioinformatics. 2011 Mar 17;12:77. (PMID: 21414208) J Alzheimers Dis. 2020;77(4):1397-1416. (PMID: 32894244) Nat Aging. 2023 Jun;3(6):661-669. (PMID: 37198279) J Biol Chem. 2013 May 24;288(21):15418-29. (PMID: 23585562) Alzheimers Res Ther. 2022 May 11;14(1):65. (PMID: 35545792) J Alzheimers Dis. 2009;18(3):665-75. (PMID: 19661626) Neurology. 2017 Jul 4;89(1):88-100. (PMID: 28592453) J Biol Chem. 2007 Nov 30;282(48):34850-7. (PMID: 17906291) Acta Neuropathol. 2021 May;141(5):709-724. (PMID: 33585983) Biochim Biophys Acta. 2003 Nov 20;1639(3):159-68. (PMID: 14636947) Alzheimers Dement. 2021 May;17(5):755-767. (PMID: 33252199) PLoS Med. 2018 Jan 25;15(1):e1002482. (PMID: 29370177) J Neuropathol Exp Neurol. 1997 Oct;56(10):1095-7. (PMID: 9329452) Neurology. 2022 Feb 15;98(7):e688-e699. (PMID: 34906975) Neurology. 1991 Apr;41(4):479-86. (PMID: 2011243) Brain. 2011 Sep;134(Pt 9):2456-77. (PMID: 21810890) Acta Neuropathol. 1991;82(4):239-59. (PMID: 1759558) JAMA. 2020 Aug 25;324(8):772-781. (PMID: 32722745) FASEB J. 2008 Sep;22(9):3224-33. (PMID: 18509201) Genomics Proteomics Bioinformatics. 2020 Feb;18(1):72-80. (PMID: 32200042) JAMA Neurol. 2021 Sep 1;78(9):1108-1117. (PMID: 34309632) Alzheimers Dement (Amst). 2021 May 27;13(1):e12204. (PMID: 34095436) J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1231-1241. (PMID: 34510001) Acta Neuropathol. 2020 Sep;140(3):267-278. (PMID: 32720099) Neurology. 2000 Jun 13;54(11):2072-7. (PMID: 10851365) Nat Med. 2022 Sep;28(9):1797-1801. (PMID: 35953717) Lancet Neurol. 2022 Jan;21(1):66-77. (PMID: 34838239) Alzheimers Res Ther. 2019 Jan 5;11(1):2. (PMID: 30611311) J Biol Chem. 2007 Aug 10;282(32):23645-54. (PMID: 17562708) Mol Neurodegener. 2017 Nov 21;12(1):87. (PMID: 29157277) Nat Rev Neurol. 2022 Jul;18(7):400-418. (PMID: 35585226) Alzheimers Dement. 2023 Oct;19(10):4507-4519. (PMID: 36876954) JAMA Neurol. 2022 Dec 1;79(12):1250-1259. (PMID: 36251300) J Mass Spectrom. 2012 May;47(5):591-603. (PMID: 22576872) Alzheimers Dement. 2023 Nov 17;:. (PMID: 37975513) EMBO Mol Med. 2023 May 8;15(5):e17123. (PMID: 36912178) Ann Neurol. 2008 Aug;64(2):168-76. (PMID: 18496870) Acta Neuropathol. 2009 Jul;118(1):53-69. (PMID: 19184068) Acta Neuropathol. 2019 Feb;137(2):279-296. (PMID: 30547227) Alzheimers Res Ther. 2021 Dec 4;13(1):198. (PMID: 34863295) Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837. (PMID: 17542011) Acta Neuropathol. 2022 Apr;143(4):487-503. (PMID: 35195758) Nat Med. 2022 Dec;28(12):2555-2562. (PMID: 36456833) Mass Spectrom Rev. 2020 May;39(3):229-244. (PMID: 28691345) Lancet Neurol. 2020 May;19(5):422-433. (PMID: 32333900) Cell. 2020 Dec 10;183(6):1699-1713.e13. (PMID: 33188775) J Intern Med. 2004 Sep;256(3):240-6. (PMID: 15324367) Alzheimers Res Ther. 2022 Feb 7;14(1):26. (PMID: 35130933) Alzheimers Dement. 2023 Nov;19(11):4967-4977. (PMID: 37078495) J Neuropathol Exp Neurol. 2014 Apr;73(4):295-304. (PMID: 24607960) Neurology. 2002 Jun 25;58(12):1791-800. (PMID: 12084879) Hybridoma. 1999 Apr;18(2):183-91. (PMID: 10380018) Front Neurol. 2015 Aug 19;6:179. (PMID: 26347708) |
| معلومات مُعتمدة: | R01 AG075336 United States AG NIA NIH HHS; R01 AG083874 United States AG NIA NIH HHS; R01 AG072641 United States AG NIA NIH HHS; R01 AG068398 United States AG NIA NIH HHS; RF1 AG025516 United States AG NIA NIH HHS; P30 AG066468 United States AG NIA NIH HHS; R01 AG073267 United States AG NIA NIH HHS; P01 AG025204 United States AG NIA NIH HHS; R01 MH121619 United States MH NIMH NIH HHS; R37 AG023651 United States AG NIA NIH HHS; U24 AG082930 United States AG NIA NIH HHS; R01 MH108509 United States MH NIMH NIH HHS; P50 AG005133 United States AG NIA NIH HHS; RF1 AG052525 United States AG NIA NIH HHS; R01 AG053952 United States AG NIA NIH HHS |
| تواريخ الأحداث: | Date Created: 20240103 Latest Revision: 20240401 |
| رمز التحديث: | 20240402 |
| مُعرف محوري في PubMed: | PMC10760276 |
| DOI: | 10.1101/2023.12.11.23299806 |
| PMID: | 38168323 |
| قاعدة البيانات: | MEDLINE |
| DOI: | 10.1101/2023.12.11.23299806 |
|---|